• Mirikizumab ELISA Kit
1 1

AntibodySystem

KDJ63101

Mirikizumab ELISA Kit

Mirikizumab ELISA Kit

Title

Catalog No.: KDJ63101

Catalog No. KDJ63101
Product name Mirikizumab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL23A has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Mirikizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Mirikizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Mirikizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Mirikizumab concentration in serum and plasma.
Stability and Storage The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method Colorimetric
Precision CV<20%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 78.23 ng/mL
Range 234.38 - 15,000 ng/mL
Recovery 80-120%
Background Mirikizumab (Eli Lilly and Company), Risankizumab (Boehringer Ingelheim and AbbVie), Tildrakizumab (Sun Pharma), Brazikumab (AstraZeneca), and Guselkumab (Janssen Biotech Inc.) are other drugs which target IL-23 and received the FDA approval for the treatment of psoriasis.
Alternative Names LY-3074828, CAS: 1884201-71-1
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기